How Has the Histone Deacetylase (HDAC) Inhibitors Market Evolved Historically and What is its Current Size?
The histone deacetylase (hdac) inhibitors market has seen considerable growth due to a variety of factors.
• The histone deacetylase (HDAC) inhibitors market has grown significantly in recent years. It will increase from $1.23 billion in 2024 to $1.33 billion in 2025, at a compound annual growth rate (CAGR) of 7.9%.
The growth is attributed to increased funding for epigenetic research, a rise in drug-resistant cancers, rising healthcare spending, increased use of HDAC inhibitors in veterinary medicine, and higher investment in bioinformatics.
What is the Forecasted Market Size and CAGR for the Histone Deacetylase (HDAC) Inhibitors Market?
The histone deacetylase (hdac) inhibitors market is expected to maintain its strong growth trajectory in upcoming years.
• The histone deacetylase (HDAC) inhibitors market is projected to reach $1.77 billion by 2029, growing at a CAGR of 7.5%.
Growth is fueled by the rise in neurodegenerative disorders, cancer awareness, drug development investments, clinical trials, and personalized medicine. Trends include technological advancements, personalized medicine, cancer immunotherapy, digital health solutions, and bioinformatics.
What Key Factors and Trends Are Driving The Growth Histone Deacetylase (HDAC) Inhibitors Market?
The rising incidence of cancer is also expected to drive the growth of the histone deacetylase inhibitors market. The increasing cancer rate is primarily due to aging populations, environmental pollutants, and lifestyle factors like smoking and diet. HDAC inhibitors help treat cancer by modifying chromatin structure, activating tumor-suppressing genes, and suppressing oncogenes, which induces cell death in cancer cells. According to the World Health Organization, cancer cases are predicted to rise to 35 million by 2050. Therefore, the growing cancer incidence is fueling the growth of the histone deacetylase inhibitors market.
What Are The Market Segments In The Histone Deacetylase (HDAC) Inhibitors Market?
The histone deacetylase (HDAC) inhibitors market covered in this report is segmented –
1) By Class: Class I HDACs, Class II HDACs, Class III HDACs, Class IV HDACs
2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors
3) By Application: Oncology, Neurology, Other Applications
4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users
Subsegments
1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8
2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10
3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7
4) By Class IV HDACs: HDAC11
Pre-Book The Histone Deacetylase (HDAC) Inhibitors Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Histone Deacetylase (HDAC) Inhibitors Market?
Leading organizations in the histone deacetylase (HDAC) inhibitors market are concentrating on devising innovative approaches, like HDAC inhibitors for cancer therapy, as a way to increase effectiveness and minimize side effects. HDAC inhibitors are a category of drug compounds utilized in cancer treatments, which work by limiting the action of HDAC enzymes that usually detach acetyl units from histone proteins. This restriction results in heightened acetylation of histones, modifying chromatin structure and impacting gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., an American company, which is known for developing innovative cancer therapies, received new HDAC Inhibitor Patents for Cancer Treatment from the U.S. Patent and Trademark Office. These innovative inhibitors are designed to target particular HDAC enzymes involved in the advancement of cancer, with the goal of obstructing abnormal gene expression patterns contributing to tumor expansion and metastasis. The patented compounds showcase improved potency and selectivity, thereby diminishing the chances of off-target impacts and enhancing safety standards for patients undergoing treatment.
Who Are the Key Players In The Histone Deacetylase (HDAC) Inhibitors Market?
Major companies operating in the histone deacetylase (HDAC) inhibitors market are:
• Bristol-Myers Squibb Company
• Novartis AG
• Merck KGaA
• Abcam plc
• Pharmacyclics LLC
• R&D Systems Inc.
• Tenaya Therapeutics Inc.
• Syndax Pharmaceuticals Inc.
• Italfarmaco SpA
• InvivoGen Corporation
• TCI Chemicals (India) Pvt. Ltd.
• 4SC AG
• Medivir AB
• Mirati Therapeutics Inc.
• Spectrum Pharmaceuticals Inc.
• Curis Inc.
• Acetylon Pharmaceuticals Inc.
• Oryzon Genomics SA
• Xynomic Pharmaceuticals Inc.
• Celleron Therapeutics Ltd.
• Midatech Pharma PLC
• Karus Therapeutics Ltd.
• Shenzhen Chipscreen Biosciences Co. Ltd.
What Are The Regional Insights Into The Histone Deacetylase (HDAC) Inhibitors Market?
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
